araag2/TREC_Precision-Medicine huggingface dataset:
Patient case: 26-year-old female with Cervical cancer. Genetic variant: STK11. Other conditions: None.

Clinical trial: Systemic Consolidation Therapy After Primary Chemoradiation Therapy for Locally Advanced Cervical Cancer

Summary: The purpose of this study is to determine the therapeutic efficacy and complications of systemic consolidation therapy with paclitaxel plus carboplatin following primary chemoradiation for locally advanced cervical cancer.

Detailed description: Systemic consolidation therapy with paclitaxel plus carboplatin (3 cycles per 3 weeks) following primary chemoradiation (3 cycles per 3 weeks) for locally advanced cervical cancer will elevate the therapeutic efficacy by removing the microscopic metastatic lesions which could not be identified by naked eye and diagnostic imaging tests.

Eligibility: Inclusion Criteria:
  -  patients who underwent three cycles of concurrent chemoradiation therapy with paclitaxel and carboplatin for non-small cell type cervical cancer stage IB2, bulky size (>4cm) IIA,IIB-IVA
  -  above 20 years
  -  GOG performance status 0-2
  -  Informed consent
  -  Platelet>100K, Hb> 10.0 g/dl, ANC>1500/mm3, Cr <1.25*upper normal limit, bilirubin<1.5mg/dl, AST & ALT<*3 upper normal limit
  -  Expected life > 6 months
  Exclusion Criteria:
  -  Peripheral neurotoxicity > NCI CTCAE grade 2
  -  Sever infection
  -  Previous history with chemotherapy or radiation therapy
  -  Pleural effusion, pericardial effusion, and ascites which could cause dyspnea > NCI grade 2
  -  Paraaortic lymph node metastasis
  -  Allergy with platinum
  -  Previous history of atrial or ventricular arrhythmia or congestive heart failure
  -  Uncontrolled infection, diabetes mellitus, hypertension, ischemic heart disease, myocardiac infarct within 6 months
  -  Severe disease such as acute or chronic renal failure and acute cerebral infarct, cerebral hemorrhage, recurrent hepatitis, liver cirrhosis, unknown fever above 39 degrees centigrade

Relevance to patient case: not relevant
Patient case: 26-year-old female with Cervical cancer. Genetic variant: STK11. Other conditions: None.

Clinical trial: Intra-Operative Lymphatic Mapping in Patients With Invasive Carcinoma of the Cervix or Endometrial Carcinoma

Summary: The purpose of this study is to learn if a surgical technique called intraoperative lymphatic mapping can accurately identify the lymph node that is at greatest risk if endometrial or cervical cancer spreads to the lymph nodes.
  Early cervical cancer is usually treated by removing the cervix, tissue around the cervix, and the upper vagina. If needed, the uterus is also removed. The treatment also includes removing lymph nodes from the pelvis. Endometrial cancer is usually treated by removing the cervix, uterus, fallopian tubes and ovaries.
  The treatment also includes removing lymph nodes from the pelvis.

Detailed description: Patients with FIGO stage I endometrial cancer or patients with FIGO stage I-IIA invasive cervical cancer and who will be undergoing surgical management to include a lymphadenectomy.
  ↓ Injection of radioisotope and preoperative lymphoscintigraphy with Tc99m either the day before or on the day of surgery by the Nuclear Medicine Department.
  ↓ Intraoperative lymphatic mapping with blue dye and gamma probe.
  ↓ Hysterectomy, Radical hysterectomy and/or radical trachelectomy and pelvic lymphadenectomy.

Eligibility: Inclusion Criteria:
  -  Patients with endometrial cancer diagnosed on endometrial biopsy or dilatation and curettage.
  -  Patients with invasive cervical cancer diagnosed on cervical biopsy or cone biopsy.
  -  Patients with a performance status of 0, 1, 2, or 3 by the Gynecologic Oncology Group criteria (Appendix).
  -  Patients with stage I to ~IIA invasive cervical cancer disease according to the International Federation of Gynecology and Obstetrics (FIGO) clinical staging criteria (Appendix).
  -  Patients with clinical stage I endometrial cancer
  -  Patients who will undergo surgery to include a hysterectomy, radical hysterectomy and/or radical trachelectomy and bilateral lymphadenectomy via laparotomy or laparoscopy
  -  Patients who have signed an approved informed consent.
  Exclusion Criteria:
  -  Patients with history of prior pelvic or para-aortic lymphadenectomy.
  -  Patients with stage IIB-IV invasive cervical cancer by FIGO criteria.
  -  Patients with recurrent endometrial or cervical cancer.
  -  Patients with prior pelvic radiation.
  -  Any patient with endometrial or cervical cancer treated with neoadjuvant chemotherapy and radiation therapy.
  -  Patients with a performance score of 4 by the Gynecologic Oncology Group criteria or who are not good surgical candidates (Appendix).
  -  Patients with grossly infected primary tumors.
  -  Patients with known allergy to triphenyl-ethane compounds.
  -  Patients with known deficiency of Glucose-G-Phosphate Dehydrogenase.
  -  Patients with known Hemolytic Anemia from Pyruvate Kinase and G6PD Deficiencies.
  -  Severe Renal Disease.

Relevance to patient case: not relevant
Patient case: 26-year-old female with Cervical cancer. Genetic variant: STK11. Other conditions: None.

Clinical trial: Identifying Biomarkers for Early Detection of Cancer in Patients With Cervical Dysplasia or Carcinoma in Situ of the Cervix

Summary: RATIONALE: Studying the genes expressed in samples of tissue from patients with abnormal cells may help doctors identify biomarkers related to cancer.
  PURPOSE: This clinical trial is identifying biomarkers for early detection of cancer in women with cervical dysplasia or carcinoma in situ of the cervix.

Detailed description: OBJECTIVES:
  Primary
  -  To identify and catalogue genetic alterations and protein changes associated with developmental stages of cervical cancer.
  -  To identify a ranked list of candidate genes that drive the transformation of premalignant lesions to tumors for further study and validation as molecular targets for novel early detection and treatment design.
  Secondary
  -  To complete genome scans at high density and analysis of gene and protein expression to identify recurrent genetic and protein changes in cancer.
  -  To confirm changes clustered to specific chromosomal regions which harbor tumor suppressors or oncogenes.
  OUTLINE: Patients undergo biopsy of cervical tissue followed by loop electrocautery excision procedure (LEEP) (removing all of the tissue surrounding and under the area biopsied). RNA, DNA, and protein is extracted from the cells to provide material for the construction of libraries for Serial Analysis of Gene Expression (SAGE analysis); for hybridization against Bacterial Artificial Chromosome Comparative Genome Hybridization arrays (BAC CGH arrays); and for analysis using protein chip arrays and proteomics. Resulting data from coded samples provide gene expression and protein profiles. The coded molecular datasets are linked, analyzed, and compared using a variety of statistical software to identify putative genes, gene alterations, and proteins of interest. Some samples may be banked for future studies.

Eligibility: DISEASE CHARACTERISTICS:
  -  Histologically or cytologically confirmed premalignant lesion, dysplasia, or carcinoma in situ of the cervix
  -  Clinically documented disease
  -  Attending Vancouver General Hospital and referred to colposcopy for loop electrocautery excision procedure (LEEP)
  PATIENT CHARACTERISTICS:
  -  Not pregnant
  -  No lack of informed consent due to language difficulty, physical and mental condition
  PRIOR CONCURRENT THERAPY:
  -  No prior operation for removal of the cervix
  -  Concurrent therapy allowed

Relevance to patient case: not relevant
Patient case: 26-year-old female with Cervical cancer. Genetic variant: STK11. Other conditions: None.

Clinical trial: Dissemination of Cervical Cancer Screening to Primary Care Physicians in Underserved Communities

Summary: Primary care physicians have an important role to play in the delivery of cancer prevention and detection services to patients. Face-to-face counseling of physicians, called academic detailing, involves a brief and focused intervention, modeled on the practices of pharmaceutical companies. This type of intervention may increase physicians' attention to preventive opportunities and increase their screening behaviors.

Detailed description: The specific aims of this proposal are:
  1. To test the hypothesis that an intervention, multi-component academic detailing, will increase the rate of physician cervical cancer screening at 3- and 6-months post-randomization, compared to the rate observed in a service-as-usual control.
  2. To develop models predicting which physician offices are most and least likely to adopt the intervention, and to generate hypotheses about tailoring the dissemination of cervical cancer screening guidelines to different physician subgroups.
  3. To conduct a cost-effectiveness analysis comparing the incremental societal costs and effects (in lives saved, life-years saved, and quality-of-life-years saved) of the cervical cancer intervention implemented in physicians' offices.
  The long-term goal of this project therefore is to reduce cervical cancer risks among ethnic and racial minorities, by influencing the screening behaviors of their primary care physicians.

Eligibility: Inclusion Criteria:
  -  Charts of female patients age 18-85 with at least one visit to the primary care provider over the last two years will be reviewed
  Exclusion Criteria:
  -  Exclusion criteria will include: diagnosis of cancer other than non-melanotic skin cancer and removal of the uterus.

Relevance to patient case: not relevant
Patient case: 26-year-old female with Cervical cancer. Genetic variant: STK11. Other conditions: None.

Clinical trial: Evaluation of ELISA Assay on Human Papilloma Viruses (HPV) Infection Population

Summary: Cervical cancer the most frequent neoplasm and the fifth mortality rate of malignancies of the women in the world. It results in about 1,000 women in Taiwan and about 200,000 women worldwide dying of cervical cancer each year. Human papilloma viruses (HPV) have been consistently implicated in causing cervical cancer especially those high-risk types (HPV 16,18,31,45) have been strongly associated with cervical cancer. Around 50-80 % of women are infected by HPV within their whole lives. However, only 1% of HPV-infected women have cervical cancer eventually. Seventy and 91% of HPV infection could be cleaned up by host immune responses within 1 and 2 years later. It shows that host immunity plays an important role in the progression, persistence, or regression of HPV infection.
  There are two main defense lines in the host immunity including innate immunity and adoptive immunity. Adoptive immunity plays more important roles in the defense of HPV infections than innate immunity. The adoptive immunity could be further divided into humoral immunity and cell-mediated immunity. Humoral immunity regulated by Th2 helper T lymphocytes to generate memory B cells to produce antibody which provide the protective function to HPV infection. Cell-mediated immunity regulated by Th1 helper T lymphocytes to induce antigen-specific cytotoxic T cells which could kill the HPV-infected cells. Although there are many researches focused on the immunity to HPV infection, there is no conclusion about the relationship between humoral and cell-mediated immunities on HPV infection and roles of humoral and cell-mediated immunities in the prognosis of HPV-infected population and cervical cancer patients.
  Our research team has focused on the establishment of platforms on cell-mediated immunity to HPV infection and on the correlation of cell-mediated immunity and prognosis of HPV-infected population and cervical cancer patients for years. In order to survey the host immunity to HPV infection more comprehensively, we propose this proposal. First, we would like to set up the platforms to elucidate the humoral immunity to HPV infection in normal population and patients with CIN lesion or cervical cancer. Second, we would to survey the correlation betweem humoral immunity and status and clinico-pathologic items of HPV-infected populations. Our research results will have a more comprehensive overview in the host immunity to HPV infection and its related diseases. It could provide more information in the prevention and treatment of HPV infection in the future.


Eligibility: Inclusion Criteria:
  -  Healthy volunteers
  -  People infected with HPV type 16 but without CIN lesions
  -  Patients with CIN lesions
  -  Patients with cervical cancer from National Taiwan University Hospital
  -  Informed consent is obtained, and the protocols are reviewed and approved by the appropriate Investigative Review Boards

Relevance to patient case: not relevant
Patient case: 26-year-old female with Cervical cancer. Genetic variant: STK11. Other conditions: None.

Clinical trial: Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer

Summary: RATIONALE: Understanding how well patients comply with their treatment regimen may help doctors determine best treatment and ongoing care for future patients.
  PURPOSE: This phase I study is looking at compliance with vaginal dilation therapy in women who have undergone radiation therapy for stage IB, stage IIA, stage IIB, stage IIIA, or stage IIIB cervical cancer or stage IA, stage IB, stage IIA, or stage IIB endometrial cancer.

Detailed description: OBJECTIVES:
  Primary
  -  To determine adherence to vaginal dilation therapy after radiotherapy in patients with early-stage IB grade 2-IIIB cervical cancer or stage IA grade 3-IIB endometrial cancer.
  -  To identify demographic, medical, and psychosocial factors associated with adherence to recommendations for vaginal dilation in these patients.
  -  To describe the sexual, marital, and non-marital dyadic functioning of these patients.
  OUTLINE: Patients from the IMPAC registry in Radiation Oncology at the University Hospitals Case Medical Center, Ireland Cancer Center complete questionnaires online or by mail. Questionnaires include the Vaginal Dilation Adherence questionnaire, the Sexual Function-Vaginal Changes Questionnaire, the Dyadic Satisfaction questionnaire, and the Physician/Nurse Recommendation of Vaginal Dilation questionnaire.

Eligibility: DISEASE CHARACTERISTICS:
  -  History of early-stage IB grade 2-IIIB cervical cancer or stage IA grade 3-IIB endometrial cancer
  -  Meets the following criteria:
  -  Received radiotherapy for this disease
  -  Treated within the last 3 years and followed for at least 6 months
  PATIENT CHARACTERISTICS:
  -  Able to read and understand English
  -  Currently with or without a sexual partner
  -  No history of other cancers
  -  No other potentially life-threatening disease
  PRIOR CONCURRENT THERAPY:
  -  See Disease Characteristics

Relevance to patient case: not relevant
Patient case: 26-year-old female with Cervical cancer. Genetic variant: STK11. Other conditions: None.

Clinical trial: Knowledge and Perceptions About Human Papillomavirus and Cervical Cancer Risk Among Young Adults

Summary: RATIONALE: Learning about young adults' knowledge and perceptions about risk factors for the human papilloma virus and cervical cancer may help doctors learn more about how to prevent human papilloma virus infection and cervical cancer in the future.
  PURPOSE: This clinical trial is studying knowledge and perceptions of the risk factors for human papilloma virus infection and cervical cancer in young adults.

Detailed description: OBJECTIVES:
  -  Describe the socio-demographic context of college students in an urban Midwestern setting.
  -  Assess knowledge of the human papillomavirus (HPV) and cervical cancer in these participants.
  -  Assess the population's perception of HPV risk.
  -  Assess the prevalence of risk behaviors that may place this population at risk for HPV.
  -  Identify the best predictors of HPV knowledge and cervical cancer knowledge.
  -  Assess vaccine knowledge and acceptance in these participants.
  OUTLINE: Participants complete the Young Adult Survey online documenting demographic data; sexual history (i.e., whether they ever had sex, age of first sexual encounter, number of life time partners, condom use, sexually transmitted diseases [STDs], and pregnancy history); cigarette use; current and past drug use; knowledge of human papillomavirus (HPV) and cervical cancer; past history of Pap tests and STD screenings; attitudes towards HPV testing; vaccine knowledge and acceptability; sources of information about HPV; source of information about cervical cancer; identification of common STDs; perceived risk of acquiring STDs; perceived risk of acquiring HPV; social support; and religion.

Eligibility: DISEASE CHARACTERISTICS:
  -  Currently enrolled in a college, university, or community college in the Greater Cleveland metropolitan area
  -  Currently single and never married
  PATIENT CHARACTERISTICS:
  -  Not specified
  PRIOR CONCURRENT THERAPY:
  -  Not specified

Relevance to patient case: not relevant
Patient case: 26-year-old female with Cervical cancer. Genetic variant: STK11. Other conditions: None.

Clinical trial: Quality of Life in Thai Women Diagnosed Cervical Cancer at King Chulalongkorn Memorial Hospital

Summary: To study the quality of life of patients earlier diagnosed for cervical cancer and cervical intraepithelial neoplasia (CIN).

Detailed description: In Thailand, age standardized incidence is 20.9 per 100,000 women-year. Treatment-related survival gain are experienced by side-effect that may reduce quality of life (QoL). We therefore, study the quality of life of patients earlier diagnosed for cervical cancer patients.

Eligibility: Inclusion Criteria:
  -  Thai patients
  -  aged more than 15 years old.
  -  Diagnosed of cervical intraepithelial neoplasia (CIN) or cervical cancer with pathological confirmation. If she has more than one diseases, the most severe will be considered as diagnosis.
  -  Not suffered from confusion or reduced level of consciousness or unable to communicate.
  Exclusion Criteria:

Relevance to patient case: not relevant
Patient case: 26-year-old female with Cervical cancer. Genetic variant: STK11. Other conditions: None.

Clinical trial: The Usefulness of Staining Lymph Nodes During Operations for Cancer Thyroid in Detecting the Nodes That Have Cancer

Summary: Detection of lymph nodes starting to be involved by cancer spreading from the thyroid gland during operation is useful. It saves the patient from having a second operation to remove these nodes later on when they become obvious. The problem is that there are many lymph nodes around the gland. The theory is that only one node will get the first spill of the tumour cells.
  In this study the investigators are trying to use an inert colored material to inject into the tumour. This should run in the same path as the tumour cells and should therefore stain the one lymph node that will be affected first should the tumour spread.
  The stained lymph node is excised and examined instantaneously for tumour affection. If it is found to be affected by the tumour, then the operation is extended to include removal of all its fellow lymph nodes. If it is found to be free from the tumour, then this patient does not have tumour spread.

Detailed description: The study includes 45 consecutive patients diagnosed as differentiated thyroid cancer by clinical examination and/or fine needle aspiration cytology (FNAC).
  Exclusion criteria are: previous neck surgery, pregnancy and known hypersensitivity to the dye used.
  An informed consent was obtained from all the patients. Peroperative workup includes history taking, clinical examination, relevant laboratory investigations including thyroid hormone assay, ultrasonography of the neck with special emphasis on the thyroid focal lesion and cervical lymph nodes. FNAC was attempted in all patients.
  All patients were then subjected to operation:
  A systematized surgical approach was adopted for the purpose of the study: this started by collar incision, development of sub-platysmal skin flaps and separation of strap muscles in the midline. This was followed by exposure of the thyroid gland; identification of the thyroid tumour; injection of the dye into the tumour; waiting for the dye to reach the lymph nodes; identifying the stained node; labeling it as the sentinel node (SLN); performing total thyroidectomy and bilateral central neck dissection.
  The resected specimen was fixed by formaldehyde, stained with hematoxylin and eosin and examined with light microscopy.
  If the SLN was found to be free of malignant deposits, it was further examined by immunohistochemical staining.
  Statistical analysis: Descriptive statistics were used to analyze demographic data. Sensitivity, specificity and predictive value of the SLN were calculated.
  The histopathological report of the excised specimen was considered the criterion standard.

Eligibility: Inclusion Criteria:
  -  Patient diagnosed to have differentiated thyroid carcinoma and has no detectable cervical lymphadenopathy.
  Exclusion Criteria:
  -  Previous neck surgery, pregnancy and known hypersensitivity to the dye used.

Relevance to patient case: not relevant